Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Mata

Showing results (111-120 of 144) with videos related to

Pageof 15
Sort By:
Circulation. Cardiovascular Imaging|January 11, 2024
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT StudyLeopoldo Pérez de Isla, Jose L Díaz-Díaz, Manuel J Romero, et al.
Atherosclerosis|March 24, 2024
Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up studyRodrigo Alonso, Raquel Arroyo-Olivares, Jose Luis Díaz-Díaz, et al.
International Journal of Cardiology|August 22, 2015
Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART studyFrancisco Fuentes, Juan F Alcala-Diaz, Gerald F Watts, et al.
European Journal of Preventive Cardiology|December 5, 2021
A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohortLeopoldo Pérez de Isla, Gerald F Watts, Ovidio Muñiz-Grijalvo, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 23, 2016
Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study)Leopoldo Pérez de Isla, Rodrigo Alonso, Nelva Mata, et al.
Journal of Clinical Lipidology|May 30, 2021
Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experienceRodrigo Alonso, Ovidio Muñiz-Grijalvo, Jose Luis Díaz-Díaz, et al.
Journal of the American College of Cardiology|March 19, 2016
Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-UpLeopoldo Perez de Isla, Rodrigo Alonso, Gerald F Watts, et al.
American Journal of Preventive Cardiology|December 21, 2023
Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national studyKhurram Nasir, Reed Mszar, Miguel Cainzos-Achirica, et al.
Circulation|April 3, 2023
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT StudyLeopoldo Pérez de Isla, Jose L Díaz-Díaz, Manuel J Romero, et al.
European Journal of Preventive Cardiology|April 30, 2014
Integrated guidance on the care of familial hypercholesterolaemia from the International FH FoundationGerald F Watts, Samuel Gidding, Anthony S Wierzbicki, et al.
Pageof 15

Showing results (111-120 of 144) with videos related to

Sort By:
Pageof 15
Circulation. Cardiovascular Imaging|January 11, 2024
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT StudyLeopoldo Pérez de Isla, Jose L Díaz-Díaz, Manuel J Romero, et al.
Atherosclerosis|March 24, 2024
Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up studyRodrigo Alonso, Raquel Arroyo-Olivares, Jose Luis Díaz-Díaz, et al.
International Journal of Cardiology|August 22, 2015
Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART studyFrancisco Fuentes, Juan F Alcala-Diaz, Gerald F Watts, et al.
European Journal of Preventive Cardiology|December 5, 2021
A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohortLeopoldo Pérez de Isla, Gerald F Watts, Ovidio Muñiz-Grijalvo, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 23, 2016
Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study)Leopoldo Pérez de Isla, Rodrigo Alonso, Nelva Mata, et al.
Journal of Clinical Lipidology|May 30, 2021
Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experienceRodrigo Alonso, Ovidio Muñiz-Grijalvo, Jose Luis Díaz-Díaz, et al.
Journal of the American College of Cardiology|March 19, 2016
Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-UpLeopoldo Perez de Isla, Rodrigo Alonso, Gerald F Watts, et al.
American Journal of Preventive Cardiology|December 21, 2023
Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national studyKhurram Nasir, Reed Mszar, Miguel Cainzos-Achirica, et al.
Circulation|April 3, 2023
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT StudyLeopoldo Pérez de Isla, Jose L Díaz-Díaz, Manuel J Romero, et al.
European Journal of Preventive Cardiology|April 30, 2014
Integrated guidance on the care of familial hypercholesterolaemia from the International FH FoundationGerald F Watts, Samuel Gidding, Anthony S Wierzbicki, et al.
Pageof 15